Journal of Cancer Therapy
Vol.5 No.6(2014), Paper ID 45950, 11
pages
DOI:10.4236/jct.2014.56061
Is 18F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?
Natalie Desiree Klass, Richard P. Baum, Michael Schmuecking, Norbert Presselt, Klaus-Michael Mueller, Thomas G. Wendt, Reiner Bonnet
Department of Radiation-Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
Department of Nuclear Medicine, Zentralklinik Bad Berka, Bad Berka, Germany
Department of Radiation-Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
Department of Thoracic Surgery, Zentralklinik Bad Berka, Bad Berka, Germany
Institute of Pathology, University of Münster, Münster, Germany
Department of Radiation Oncology, University of Jena, Jena, Germany
Department of Pneumology, Zentralklinik Bad Berka, Bad Berka, Germany
Copyright © 2014 Natalie Desiree Klass, Richard P. Baum, Michael Schmuecking, Norbert Presselt, Klaus-Michael Mueller, Thomas G. Wendt, Reiner Bonnet et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Klass, N. , Baum, R. , Schmuecking, M. , Presselt, N. , Mueller, K. , Wendt, T. and Bonnet, R. (2014) Is
18F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?.
Journal of Cancer Therapy,
5, 531-541. doi:
10.4236/jct.2014.56061.